118 related articles for article (PubMed ID: 31526911)
1. Discovery and optimization of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one derivatives as mTORC1/mTORC2 dual inhibitors.
Hu S; Zhao Z; Yan H
Bioorg Chem; 2019 Nov; 92():103232. PubMed ID: 31526911
[TBL] [Abstract][Full Text] [Related]
2. Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer.
Chaube UJ; Rawal R; Jha AB; Variya B; Bhatt HG
Bioorg Chem; 2021 Jan; 106():104501. PubMed ID: 33280832
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of N
Zhao Z; Wang H; Tian N; Yan H; Wang J
Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100213. PubMed ID: 34368988
[TBL] [Abstract][Full Text] [Related]
4. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors.
Reddy GL; Guru SK; Srinivas M; Pathania AS; Mahajan P; Nargotra A; Bhushan S; Vishwakarma RA; Sawant SD
Eur J Med Chem; 2014 Jun; 80():201-8. PubMed ID: 24780597
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
Liu Y; Zhang C; Zhang H; Li M; Yuan J; Zhang Y; Zhou J; Guo H; Zhao L; Du Y; Wang L; Ren L
Eur J Med Chem; 2015 Mar; 93():142-55. PubMed ID: 25668494
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one Derivatives as a PI3Kα Inhibitor.
Hu S; Zhao Z; Ni Y; Xin H; Yan H; Song X
Biol Pharm Bull; 2019; 42(6):1013-1018. PubMed ID: 31155575
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
Gangjee A; Lin X; Kisliuk RL; McGuire JJ
J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
[TBL] [Abstract][Full Text] [Related]
9. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
10. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
12. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
14. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
16. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
17. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
18. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
Gao T; Zhang C; Shi X; Guo R; Zhang K; Gu J; Li L; Li S; Zheng Q; Cui M; Cui M; Gao X; Liu Y; Wang L
Eur J Med Chem; 2019 Sep; 178():329-340. PubMed ID: 31200235
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
20. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
